Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its target price decreased by Morgan Stanley from $130.00 to $110.00 in a research note issued to investors on Friday, MarketBeat.com reports. Morgan Stanley currently has an overweight rating on the stock.
A number of other analysts also recently commented on IONS. Jefferies Financial Group dropped their target price on shares of Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday. The Goldman Sachs Group increased their price objective on Ionis Pharmaceuticals from $74.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Raymond James Financial set a $87.00 price objective on Ionis Pharmaceuticals in a research note on Thursday. Wall Street Zen raised Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, HC Wainwright boosted their price objective on Ionis Pharmaceuticals from $125.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Eighteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.80.
Read Our Latest Research Report on IONS
Ionis Pharmaceuticals Price Performance
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.29. The business had revenue of $246.09 million during the quarter, compared to analysts’ expectations of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The company’s quarterly revenue was up 86.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.93) earnings per share. On average, equities analysts forecast that Ionis Pharmaceuticals will post -3.69 EPS for the current year.
Insider Activity
In other Ionis Pharmaceuticals news, EVP Holly B. Kordasiewicz sold 60,846 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $73.41, for a total transaction of $4,466,704.86. Following the transaction, the executive vice president owned 22,458 shares of the company’s stock, valued at $1,648,641.78. The trade was a 73.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP C Frank Bennett sold 15,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $85.46, for a total value of $1,281,900.00. Following the completion of the transaction, the executive vice president owned 75,018 shares in the company, valued at $6,411,038.28. This represents a 16.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 244,038 shares of company stock valued at $19,139,399 in the last ninety days. Corporate insiders own 1.81% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in IONS. Brown Brothers Harriman & Co. acquired a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at $27,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Ionis Pharmaceuticals in the first quarter worth $30,000. Quarry LP purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth $38,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth $47,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Ionis Pharmaceuticals in the 4th quarter worth about $47,000. Institutional investors and hedge funds own 93.86% of the company’s stock.
Key Ionis Pharmaceuticals News
Here are the key news stories impacting Ionis Pharmaceuticals this week:
- Negative Sentiment: Ionis and AstraZeneca disclosed that the Phase 3 CARDIO-TTRansform trial for eplontersen in ATTR-CM failed to hit its main efficacy goal, a major setback for a key partnered drug. Article Title
- Negative Sentiment: Reuters reported that the AstraZeneca-Ionis heart drug also missed its main goal of reducing cardiovascular deaths and recurrent heart problems, reinforcing investor concerns about the program. Article Title
- Negative Sentiment: Several insiders, including an executive vice president and a director, disclosed stock sales under pre-arranged 10b5-1 plans, adding to near-term caution.
- Negative Sentiment: Traders bought an unusually large number of put options, suggesting some market participants are positioning for further downside.
- Neutral Sentiment: Multiple analysts cut price targets on IONS, but most kept Buy/Overweight ratings, indicating valuation confidence even after the setback. Article Title
- Neutral Sentiment: HC Wainwright, Morgan Stanley, Canaccord Genuity, and Needham all lowered targets, with Needham trimming its target to $86 from $105 while maintaining a Buy rating. Article Title
- Neutral Sentiment: Ionis updated FY2026 revenue guidance to $875 million-$900 million, roughly in line with expectations, which does little to offset the clinical disappointment.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Read More
- Five stocks we like better than Ionis Pharmaceuticals
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
